<DOC>
	<DOCNO>NCT02554266</DOCNO>
	<brief_summary>The study enroll patient present claudication , critical limb ischemia ( Rutherford Category 3- 5 ) angiographically significant ( ≥ 70 % ) native artery lesion appropriate angioplasty knee . Subjects treat Lutonix Drug Coated Balloon ( DCB ) carry CE Mark per current IFU follow clinically minimum 2 year .</brief_summary>
	<brief_title>Registry Investigating Clinical Use Safety Lutonix Drug Coated Balloon Treatment BTK Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Male nonpregnant , nonbreastfeeding female ≥18 year age ; 2 . Rutherford Clinical Category 35 ; 3 . Patient willing provide inform consent , willing comply protocolrequired follow visit recommend medication regimen ; 4 . Significant stenosis ( ≥70 % ) occlusion one native artery ( ) tibial plateau tibiotalar joint appropriate angioplasty per operator visual assessment ; 5 . Lesion ( ) treat available Lutonix DCB device size matrix per current Instructions Use ( IFU ) ; 6 . Target vessel ( ) reconstitute ( ) ankle inline flow least one patent ( &lt; 50 % residual stenosis ) inframalleolar outflow vessel ( plan treatment belowtheankle allow ) . NOTE : Outflow must assess AFTER predilatation NOTE : More one artery allow , target vessel MUST demonstrate inline inframalleolar outflow . Patients exclude ANY follow condition apply : 1 . Patient currently participate investigational drug device study yet reach primary endpoint previously enrol registry ( i.e . Lutonix BTK registry ) ; 2 . Inability take recommended medication state IFU noncontrollable allergy contrast ; 3 . Neurotrophic ulcer heel pressure ulcer ulcer potentially involve calcaneus ( index limb ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>